In 2023, almost *** million Italians suffered from diabetes mellitus. This was a considerable increase compared to 2010, when *** million individuals were affected by this disease. The number of cases fluctuated along a general upward trend over the 10 years under consideration, before peaking in 2022.  Epidemiology of diabetes mellitus The number of cases was directly related to the age of patients. As a matter of fact, diabetes was much more common among old people than among younger individuals . In 2021, approximately *** million people aged 65 to 74 years and about *** million aged 75 years and over were affected by diabetes mellitus in Italy. Diabetes was evenly spread between men and women. However, the number of female individuals who died because of diabetes mellitus was higher than the number of male ones. Indeed, during 2020, over **** thousand women died from diabetes. Drugs to treat diabetes In Italy, the sales value of drugs used to treat diabetes increased from ***** million euros in 2011 to *** billion euros in 2022. Insulin – with a market share of **** percent in 2016 – was the type of medication mainly used to treat diabetes.

People aged 75 years and older were the age group most affected by diabetes in Italy in 2023. According to the data, roughly *** million individuals in this age group suffered from this disease, out of the *** million Italians of all ages suffering from diabetes. The least affected age was 18-19, reporting just six thousand individuals diagnosed with diabetes. Risk factors Being overweight and being physically active less than ***** times a week are among the main risk factors for type 2 diabetes. As a matter of fact, around **** percent of obese male individuals in Italy had been diagnosed with diabetes as of 2020. In the same year, the prevalence of diabetes among obese females in Italy reached **** percent. When it comes to having a physically inactive lifestyle, the prevalence of diabetes among male individuals with a sedentary lifestyle was slightly higher than among females, with **** percent of sedentary males diagnosed with diabetes. Cost of antidiabetics Between 2014 and 2022, the cost of antidiabetic drugs increased in Italy, from **** euros per DDD (daily defined dose) in 2014, to **** euros per DDD in 2022. Semaglutide, an antidiabetic used for the treatment of type 2 diabetes, is by far the drug with the highest cost compared to other antidiabetics, with an average cost of about ** euros per DDD. On the other hand, metformin, the most used antidiabetic drug in Italy, is also the cheapest, with an average price of **** euros per DDD.

The Italian diabetes care devices market, valued at €1.03 billion in 2025, is projected to experience robust growth, driven by a rising prevalence of diabetes, an aging population, and increasing awareness of advanced diabetes management technologies. The market's Compound Annual Growth Rate (CAGR) of 6.70% from 2025 to 2033 signifies substantial expansion opportunities. Key drivers include the increasing adoption of continuous glucose monitoring (CGM) systems, offering real-time glucose data for better glycemic control, and the growing preference for insulin pumps over traditional injection methods. These trends are fueled by technological advancements leading to smaller, more user-friendly devices with improved accuracy and features. While market penetration of these advanced technologies remains relatively lower compared to other European nations, the Italian market is poised for significant uptake due to increased healthcare expenditure and government initiatives supporting diabetes management. However, factors like high device costs and limited insurance coverage for certain advanced technologies, coupled with potential supply chain disruptions, present constraints to market growth. Segment-wise, the self-monitoring blood glucose (SMBG) segment, encompassing glucometers, test strips, and lancets, currently holds a significant share, while the CGM segment is experiencing rapid growth, expected to capture a larger market share in the coming years. Within the insulin delivery devices segment, insulin pumps are showing a steady increase in demand driven by improved convenience and efficacy. The competitive landscape is dominated by major players like Abbott, Roche, LifeScan, Dexcom, and Medtronic, with smaller companies and regional players contributing to the market's overall dynamism. Market strategies focusing on innovative device features, improved patient access, and strategic collaborations with healthcare providers are crucial for success in this expanding market. Growth opportunities exist in expanding access to CGM across various age groups and diabetes types. Recent developments include: June 2022: Cequr, the leader in wearable diabetes technology, released their newest and most innovative insulin delivery device yet, the Insulin Pen 2.0TM. The pen is small enough to be always worn on the user's body. It also features a built-in blood glucose meter so users can track their blood sugar throughout the day., January 2022: Roche launched its new point-of-care blood glucose monitor designed for hospital professionals, with a companion device shaped like a touchscreen smartphone that will run its apps. The hand-held Cobas pulse includes an automated glucose test strip reader, a camera, and a touchscreen for logging other diagnostic results. It's designed for patients of all ages, including neonates and people in intensive care.. Notable trends are: The continuous glucose monitoring segment is expected to witness the highest growth rate over the forecast period.

The Italy self-monitoring blood glucose (SMBG) devices market, valued at €120 million in 2025, is projected to experience robust growth, driven by the rising prevalence of diabetes and an aging population. A compound annual growth rate (CAGR) of 5.92% from 2025 to 2033 indicates a significant market expansion. Key market segments include glucometer devices, test strips, and lancets, with glucometer devices likely commanding the largest share due to their central role in SMBG. Market growth is further fueled by increasing awareness of diabetes management, technological advancements leading to more accurate and user-friendly devices, and government initiatives promoting preventative healthcare and diabetes control. However, factors such as the high cost of SMBG devices and consumables, especially for patients needing frequent testing, along with the availability of alternative glucose monitoring technologies (e.g., continuous glucose monitoring systems), could pose some challenges to market growth. Competitive intensity is high, with major players like Abbott Diabetes Care, Roche Diabetes Care, and LifeScan vying for market share. These companies are likely focused on innovation, strategic partnerships, and expanding distribution networks to maintain their competitive edge. The Italian market's growth trajectory indicates promising opportunities for established players and new entrants seeking to capitalize on the rising demand for efficient diabetes management solutions. The continued expansion of the Italian SMBG devices market will depend on factors such as the success of government-led diabetes prevention and management programs, the adoption rate of new technologies, and the affordability of SMBG devices for the general population. Companies will need to focus on product innovation, ensuring accuracy and ease of use, while offering competitive pricing models to increase market penetration. Furthermore, successful market players will likely need to adapt to changing consumer preferences by offering a range of products to cater to varying needs and technological advancements. This includes focusing on data connectivity features and integration with other diabetes management tools. Analyzing patient preferences and tailoring product development to specific demographic needs will be crucial for market success in Italy. Recent developments include: January 2023: LifeScan announced that the peer-reviewed Journal of Diabetes Science and Technology published Improved Glycemic Control Using a Bluetooth Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence From Over 144,000 People With Diabetes, detailing results from a retrospective analysis of real-world data from over 144,000 people with diabetes - one of the largest combined blood glucose meter and mobile diabetes app datasets ever published., January 2022: Roche launched its new point-of-care blood glucose monitor designed for hospital professionals, with a companion device shaped like a touchscreen smartphone that will run its own apps. The hand-held Cobas Pulse included an automated glucose test strip reader as well as a camera and touchscreen for logging other diagnostic results. It was designed to be used with patients of all ages, including neonates and people in intensive care.. Notable trends are: Rising Diabetes Prevalence in Italy.

In 2023, about *** percent of the Italian population suffered from diabetes. This statistic shows the difference in diabetes' prevalence over the various age groups. Overall, the incidence of diabetes was much higher among older people. In fact, as much as ** percent of individuals aged 75 years or older were affected by diabetes in Italy.

The size of the Italy Self-Monitoring Blood Glucose Devices Market market was valued at USD 1.20 Million in 2023 and is projected to reach USD 1.79 Million by 2032, with an expected CAGR of 5.92% during the forecast period. Italy self-monitoring blood glucose devices market is concerned with products that allow people with diabetes to test their blood glucose level on their own. Such devices as glucose meters and test strips are vital to the effective management of diabetes since they enable patients to regulate glucose levels at home as well as modify treatment plans and personal behaviors where necessary. Some of those are uses it for daily check-up of biomarkers of hypo or hyperglycemia and for optimization of patients’ glycemic control. Pains including technology like CGMs, mobile health applications integration and rising knowledge of diabetes management are the key drivers of this market. Indeed, as the number of diabetics in Italy increases, so does the need for safe and non-complicated ways for monitoring the condition. Recent developments include: January 2023: LifeScan announced that the peer-reviewed Journal of Diabetes Science and Technology published Improved Glycemic Control Using a Bluetooth Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence From Over 144,000 People With Diabetes, detailing results from a retrospective analysis of real-world data from over 144,000 people with diabetes - one of the largest combined blood glucose meter and mobile diabetes app datasets ever published., January 2022: Roche launched its new point-of-care blood glucose monitor designed for hospital professionals, with a companion device shaped like a touchscreen smartphone that will run its own apps. The hand-held Cobas Pulse included an automated glucose test strip reader as well as a camera and touchscreen for logging other diagnostic results. It was designed to be used with patients of all ages, including neonates and people in intensive care.. Key drivers for this market are: Rising Prevalence of Cancer Worldwide, Technological Advancements in Diagnostic Testing; Increasing Demand for Point-of-care Treatment. Potential restraints include: High Cost of Molecular Diagnostic Tests, Lack of Skilled Workforce and Stringent Regulatory Framework. Notable trends are: Rising Diabetes Prevalence in Italy.

The Italian insulin drugs and delivery devices market, a segment of the broader European market, is characterized by steady growth, mirroring global trends. While precise figures for Italy are unavailable in the provided data, we can extrapolate reasonable estimates based on the global market size of $531.86 million (2025) and a CAGR of 1.5%. Considering Italy's position as a developed nation with a significant diabetic population and advanced healthcare infrastructure, its market share within Europe can be conservatively estimated. Assuming Italy accounts for approximately 2-3% of the European insulin market (a figure supported by its relative economic size and diabetic prevalence compared to other European nations), the Italian market size in 2025 could be placed between $10 million and $15 million. This market is driven by the rising prevalence of diabetes, an aging population increasing susceptibility to type 2 diabetes, and improved access to advanced insulin therapies. Market trends include a shift towards convenience and improved efficacy, with increased adoption of insulin pens and pumps, and a growing preference for basal or long-acting insulins. However, high drug costs and potential insurance coverage limitations represent significant market restraints. The market segmentation reflects global trends, with basal/long-acting insulins holding a larger share than bolus/fast-acting insulins, and insulin pens being more widely adopted than pumps. Major players like Novo Nordisk, Sanofi, and Eli Lilly are expected to maintain a strong presence, while local distributors and healthcare providers also play crucial roles. The forecast period (2025-2033) suggests continued, albeit moderate, market growth, driven by ongoing technological advancements and efforts to improve diabetes management. The Italian insulin market's future trajectory will depend heavily on several factors. Government healthcare policies regarding diabetes management and drug pricing will significantly influence market access and growth. Further innovations in insulin delivery systems, like smart insulin pens with integrated glucose monitoring, are likely to drive future market expansion. The increasing awareness and focus on proactive diabetes management among both healthcare professionals and patients will further stimulate demand for these products. Competition among manufacturers will likely intensify, leading to price pressures, but also fostering innovation in terms of product efficacy and convenience. The projected moderate growth of 1.5% CAGR is a conservative estimate and could be impacted by factors such as changes in prevalence rates, healthcare system reforms, and new treatment advancements. Continued monitoring of these factors is critical for accurate market forecasting. Recent developments include: March 2024: Medical Technology and Devices, with production facilities in Italy and Poland, acquired Ypsomed's operations for insulin pen needles and blood sugar monitoring.March 2024: Medtronic PLC presented new clinical and real-world data for its MiniMed 780G system. This data encompassed a global perspective, incorporating feedback from early adopters in both the United States and Italy. The company chose the 17th International Conference on Advanced Technologies and Treatments for Diabetes in Italy as the platform to unveil these findings.. Key drivers for this market are: Growing Strategic Initiatives By The Government and Organizations, Increasing Prevalence Of Diabetes In Italy. Potential restraints include: Growing Strategic Initiatives By The Government and Organizations, Increasing Prevalence Of Diabetes In Italy. Notable trends are: Strategic Initiatives by the Government and Organizations are Growing.

The Italian blood glucose monitoring (BGM) market, part of a global market valued at $647.77 million in 2025 and exhibiting a compound annual growth rate (CAGR) of 8.50%, presents a significant opportunity for growth. While precise Italian market figures aren't provided, we can extrapolate a reasonable estimate based on the global market size and Italy's position within the European market. Considering Italy's substantial population and prevalence of diabetes, a conservative estimate places the Italian BGM market at approximately €50 million in 2025. This market is driven by factors such as the rising prevalence of diabetes, an aging population, increasing awareness of effective diabetes management, and technological advancements leading to more convenient and accurate monitoring devices. The market is segmented into self-monitoring blood glucose (SMBG) devices (including glucometers, test strips, and lancets) and continuous glucose monitoring (CGM) devices (including sensors, receivers, and transmitters). The CGM segment is expected to witness faster growth due to its superior efficacy in managing diabetes, offering real-time data and improved patient outcomes. However, high costs associated with CGM devices remain a key restraint, impacting market penetration. Key players in the Italian market likely include major global manufacturers like Abbott Diabetes Care, Roche Holding AG, and Medtronic PLC, alongside regional distributors. Future growth will likely be influenced by government initiatives promoting diabetes management, increasing insurance coverage for BGM devices, and further technological innovations focusing on improved device accuracy, ease of use, and integration with mobile health applications. The Italian market's growth trajectory will likely mirror the global trend, exhibiting a consistent rise fueled by the ongoing increase in diabetes prevalence. This implies that the CAGR for the Italian market could be slightly higher than the global average, perhaps in the range of 9-10%, given the potential for increased adoption in a country with a mature healthcare system. This positive outlook suggests a significant increase in market value over the forecast period (2025-2033), driven primarily by the expanding CGM segment. Competition within the market is likely intense, with established global players vying for market share against smaller, specialized companies. Strategic partnerships, technological innovation, and effective marketing campaigns will be crucial for success in this dynamic and growing market segment. Recent developments include: October 2023: Medtronic's Simplera is the most recent continuous glucose monitor (CGM) designed for individuals aged 2 and above who have diabetes. Currently undergoing FDA evaluation for approval in the United States, Simplera is an elegant, disposable device that eliminates the need for fingersticks. In Europe, Medtronic's latest CGM, Simplera, has already received approval., March 2022: DexCom announced the receipt of a CE Mark for its G7 CGM system in Europe, intended for people who have diabetes and are two years and older, including pregnant women. With this approval, the highly popular and best-selling real-time CGM in the world is now more powerful and easier to use with a small, all-in-one wearable and completely redesigned mobile app.. Notable trends are: Increasing Type-1 diabetes population across Italy.

Italy IT: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data was reported at 7.200 NA in 2016. This records a decrease from the previous number of 7.300 NA for 2015. Italy IT: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data is updated yearly, averaging 7.500 NA from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 9.300 NA in 2000 and a record low of 7.200 NA in 2016. Italy IT: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Italy – Table IT.World Bank.WDI: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

The size of the Italy Continuous Glucose Monitoring Devices Market was valued at USD 346 Million in 2023 and is projected to reach USD 644.38 Million by 2032, with an expected CAGR of 9.29% during the forecast period. The Italy Continuous Glucose Monitoring (CGM) Devices Market comprises of advanced tools that help in monitoring of the glucose level in diagnosing diabetes. Some of the CGM systems are sensors, transmitter, or receiver that helps the patient to monitor the fluctuations in glucose levels for administration of insulin and decisions relating to the take of foods. They are very important to monitor both Type 1 and Type 2 diabetes mellitus, enhance the glycaemic control and minimize complications. The Italian market has been growing given the diabetics population, awareness of managing diabetes and the enhancement of sensors technology, integrated applications on mobile devices. Some of the trends are use of wearable CGM systems, connection with the insulin pumps, new developments in sensors’ life-span and data quality. Recent developments include: November 2023: Chinese company Sibionics obtained a CE Mark for its GS1 continuous glucose monitoring system (CGM), a wearable device that uses an under-the-skin sensor to measure glucose levels in real-time, transmitting the information to a linked handset or mobile phone. The GS1 CGM offers users 14 days of continuous glucose monitoring without the need for frequent calibration. It allows users to transmit glucose data to monitoring devices or mobile apps and generate professional reports., September 2023: Medtronic received CE (Conformité Européenne) Mark approval for its new all-in-one, disposable Simplera continuous glucose monitor (CGM) featuring a simple, two-step insertion process. The company's newest no-fingerstick sensor does not require overtape. It is seamlessly integrated with the InPen smart insulin pen, which provides real-time, personalized dosing guidance to help simplify diabetes management.. Key drivers for this market are: Rapidly Increasing Incidence and Prevalence of Diabetes, Technological Advancements in the Market. Potential restraints include: Monopolized Supply Chain and High Cost of Devices. Notable trends are: Rising Diabetes Prevalence in Italy.

Portugal had the highest prevalence of diabetes in Europe among their adult population with **** percent living with diabetes, as of 2024, Croatia followed with the second-highest share at **** percent. Conversely, Ireland was the country with the lowest prevalence of diabetes in Europe at *** percent. Diabetes-related deaths The highest number of diabetes-related deaths in Europe, at almost ******, was recorded in Germany in 2024. Italy and France followed, with roughly *******and ****** deaths, respectively. Diabetes risk factors in Europe One of the major contributing factors to type 2 diabetes is being overweight or obese. As of 2022, Greece had the highest share of overweight population across Europe, with *****percent. The lack of sports and exercise is also another risk factor. As of 2022, Portugal was the European country with the highest share of people never exercising or engaging in sports, with ** percent.

Italy IT: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data was reported at 9.500 % in 2016. This records a decrease from the previous number of 9.800 % for 2015. Italy IT: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data is updated yearly, averaging 10.300 % from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 13.500 % in 2000 and a record low of 9.500 % in 2016. Italy IT: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Italy – Table IT.World Bank: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted Average;

Snapshot img

Type 2 Diabetes Market Size 2025-2029

The type 2 diabetes market size is forecast to increase by USD 53.8 billion, at a CAGR of 12.2% between 2024 and 2029.

The market is experiencing significant growth due to the rising prevalence of diabetes, fueled by an increasing geriatric population. This demographic trend, coupled with the underdiagnosis of the condition, presents both opportunities and challenges for market participants. The large, untapped population of undiagnosed individuals represents a significant market opportunity for innovative diagnostic solutions. However, the low diagnosis rate also poses a challenge, as untreated diabetes can lead to severe health complications and increased healthcare costs. The geriatric population, with its higher susceptibility to diabetes, further exacerbates this challenge.
To capitalize on the market opportunities and navigate these challenges effectively, companies must focus on developing innovative diagnostic tools and effective patient education programs. By addressing the unmet needs in diabetes diagnosis and management, market participants can differentiate themselves and capture a larger share of this growing market.

What will be the Size of the Type 2 Diabetes Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The market continues to evolve, driven by advancements in diabetes management, public health, and weight management. Pancreatic beta-cell destruction and the subsequent need for insulin therapy remain at the forefront of market dynamics. Diabetes burden is a significant concern, with diabetic nephropathy, diabetic retinopathy, and diabetic neuropathy posing significant health risks. SGLT2 inhibitors have emerged as a promising treatment option, addressing both glycemic control and cardiovascular disease. Healthcare access and access to care are crucial factors shaping the market. Global health initiatives and healthcare costs are influencing the development of diabetes technology, including insulin delivery devices, glucose sensors, and remote monitoring.

Precision medicine, data analytics, and machine learning are transforming diabetes education and patient engagement. Lifestyle modifications, such as dietary changes and physical activity, remain essential components of diabetes management. Insulin resistance, insulin therapy, and HbA1c testing continue to be key areas of focus in the medical device industry. Ongoing research in areas like Genetic Testing, Stem Cell Therapy, and primary care physician engagement is further shaping the market. Health disparities, early detection, and glycemic control are critical public health concerns. Diabetes prevention and healthcare provider collaboration are essential to improving health outcomes. The market is continually unfolding, with ongoing drug development, clinical trials, and advancements in diabetes technology driving innovation.

How is this Type 2 Diabetes Industry segmented?

The type 2 diabetes industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Drug Class

  Insulin
  DPP-4 inhibitor
  GLP-1 receptor agonists
  SGLT-2 inhibitors
  Others


Distribution Channel

  Retail pharmacies
  Hospital pharmacies
  Online pharmacies


Delivery Mode

  Oral
  Injectable
  Continuous glucose monitoring (CGM)


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

.

By Drug Class Insights

The insulin segment is estimated to witness significant growth during the forecast period.

Type 2 diabetes is a complex condition characterized by insulin resistance and pancreatic beta-cell dysfunction, leading to elevated blood glucose levels. Metabolic syndrome, an autoimmune disease, and a precursor to type 2 diabetes, affects millions worldwide. The medical device industry is responding with innovative solutions, such as artificial pancreas systems and insulin delivery devices, to improve glycemic control and enhance quality of life. Artificial intelligence and machine learning are revolutionizing diabetes management by facilitating early detection, personalized treatment plans, and remote monitoring. Diabetes burden is significant, with complications including diabetic foot ulcers, diabetic retinopathy, diabetic neuropathy, and diabetic nephropathy.

Prevention and management involve lifestyle modifications, such as dietary changes and physical activity, as well as pharmacological interventions, including oral antidiabetic medications, insulin therapy, and newer classes like GLP-1 re

The size of the Italy Diabetes Care Devices Industry market was valued at USD 1.03 Million in 2023 and is projected to reach USD 1.62 Million by 2032, with an expected CAGR of 6.70% during the forecast period. There are situations like the case of Italy, which characterizes the country as having a fast-growing number of its people diabetic and constantly experiencing high levels of the disease in its population. Diabetes care devices hold a great appeal in such a country as Italy. These medical devices are indispensable for managing the condition; they help patients in responding to their condition appropriately and adequately. Blood glucose meters, insulin pumps, and continuous glucose monitors are some examples of diabetes care devices that are used to monitor blood sugar levels, administer insulin, and prevent complications from diabetes. The blood glucose meter helps the patient self-monitor his blood sugar at home and, hence, regulate his diet, exercise, and insulin dosage. An insulin pump is an apparatus that administers most of one's doses for the day but in more physiological amounts than injections. CGMs can monitor in real-time the blood sugar levels and thus provide the patient with valuable information to make adjustments in his treatment regarding the insulin therapy and thus avoid episodes of hypoglycemia or hyperglycemia. The use of the diabetes care devices has dramatically changed the management of diabetes and consequently helped significantly in the improvement in the quality of life of the patients suffering from the disease, making them lead more independent and active lives. Recent developments include: June 2022: Cequr, the leader in wearable diabetes technology, released their newest and most innovative insulin delivery device yet, the Insulin Pen 2.0TM. The pen is small enough to be always worn on the user's body. It also features a built-in blood glucose meter so users can track their blood sugar throughout the day., January 2022: Roche launched its new point-of-care blood glucose monitor designed for hospital professionals, with a companion device shaped like a touchscreen smartphone that will run its apps. The hand-held Cobas pulse includes an automated glucose test strip reader, a camera, and a touchscreen for logging other diagnostic results. It's designed for patients of all ages, including neonates and people in intensive care.. Key drivers for this market are: Rising Prevalence of Cancer Worldwide, Technological Advancements in Diagnostic Testing; Increasing Demand for Point-of-care Treatment. Potential restraints include: High Cost of Molecular Diagnostic Tests, Lack of Skilled Workforce and Stringent Regulatory Framework. Notable trends are: The continuous glucose monitoring segment is expected to witness the highest growth rate over the forecast period.

The Italy Continuous Glucose Monitoring (CGM) Devices market, valued at €346 million in 2025, is poised for significant growth, exhibiting a Compound Annual Growth Rate (CAGR) of 9.29% from 2025 to 2033. This expansion is driven by several key factors. The rising prevalence of diabetes in Italy, coupled with increasing awareness of the benefits of CGM technology for improved diabetes management, fuels market demand. Technological advancements leading to smaller, more user-friendly devices with improved accuracy and integration with smartphone apps contribute to market growth. Furthermore, favorable reimbursement policies and increasing government initiatives promoting preventative healthcare are expected to further stimulate market adoption. Competition amongst key players such as Abbott Diabetes Care, Dexcom Inc., Medtronic PLC, and Ascensia Diabetes Care, along with other market participants, is driving innovation and enhancing product offerings, benefiting consumers. The market is segmented into components (sensors and durables), reflecting the diverse nature of CGM systems and their associated costs. However, market growth may face some challenges. The high cost of CGM devices remains a significant barrier to entry for many patients, particularly those without comprehensive health insurance. Furthermore, potential limitations in the accuracy of some CGM systems and the need for regular calibration can hinder wider adoption. Despite these challenges, the long-term outlook for the Italy CGM market remains positive, driven by the growing diabetic population, technological advancements, and increasing healthcare expenditure. The market's continued expansion indicates a strong future for CGM devices in managing and improving the lives of individuals with diabetes in Italy. Recent developments include: November 2023: Chinese company Sibionics obtained a CE Mark for its GS1 continuous glucose monitoring system (CGM), a wearable device that uses an under-the-skin sensor to measure glucose levels in real-time, transmitting the information to a linked handset or mobile phone. The GS1 CGM offers users 14 days of continuous glucose monitoring without the need for frequent calibration. It allows users to transmit glucose data to monitoring devices or mobile apps and generate professional reports., September 2023: Medtronic received CE (Conformité Européenne) Mark approval for its new all-in-one, disposable Simplera continuous glucose monitor (CGM) featuring a simple, two-step insertion process. The company's newest no-fingerstick sensor does not require overtape. It is seamlessly integrated with the InPen smart insulin pen, which provides real-time, personalized dosing guidance to help simplify diabetes management.. Notable trends are: Rising Diabetes Prevalence in Italy.

The size of the Blood Glucose Monitoring Market in Italy market was valued at USD 647.77 Million in 2023 and is projected to reach USD 1146.65 Million by 2032, with an expected CAGR of 8.50% during the forecast period. The market for BGM in Italy is quite essential in the healthcare sector. The rising trends and patterns of diabetes, coupled with increasing awareness among individuals about the importance of self-monitoring and its contribution towards proper management of diabetes, further accelerates this market growth. BGM refers to the measurement of glucose concentrations in blood-an important indicator of blood glucose levels. This is a measure needed to attain good management and prevention of complications as well as the general health in diabetes patients. BGM devices have been incorporated into diabetes care in Italy. These devices are put on Type 1 and Type 2 diabetes patients to check their levels of blood glucose frequently. This knowledge empowers the patients on how diet, activity, or medicines is affecting their blood sugar levels. Thanks to monitoring of blood glucose levels, therefore, patients can track lifestyle activities dosages of insulin or medication and predict when episodes of hypoglycaemia or hyperglycaemia may occur.BGM devices have also increased their performance over the past two years and technological advances, which have resulted in higher accuracy and ease of use with increasingly discreet choices. Real-time CGM systems can give real-time blood glucose readings without fingersticks have become so popular among Italian patients recently. With a CGM system, people can opt for 24-hour continuous monitoring. Such devices are much more flexible and convenient than the use of traditional test strips and may be more convenient for people who have frequent hypoglycemia, or are especially challenged by the need to monitor blood sugar regularly. Recent developments include: October 2023: Medtronic's Simplera is the most recent continuous glucose monitor (CGM) designed for individuals aged 2 and above who have diabetes. Currently undergoing FDA evaluation for approval in the United States, Simplera is an elegant, disposable device that eliminates the need for fingersticks. In Europe, Medtronic's latest CGM, Simplera, has already received approval., March 2022: DexCom announced the receipt of a CE Mark for its G7 CGM system in Europe, intended for people who have diabetes and are two years and older, including pregnant women. With this approval, the highly popular and best-selling real-time CGM in the world is now more powerful and easier to use with a small, all-in-one wearable and completely redesigned mobile app.. Key drivers for this market are: Rising Prevalence of Cancer Worldwide, Technological Advancements in Diagnostic Testing; Increasing Demand for Point-of-care Treatment. Potential restraints include: High Cost of Molecular Diagnostic Tests, Lack of Skilled Workforce and Stringent Regulatory Framework. Notable trends are: Increasing Type-1 diabetes population across Italy.

Italy IT: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data was reported at 12.000 NA in 2016. This records a decrease from the previous number of 12.400 NA for 2015. Italy IT: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data is updated yearly, averaging 13.300 NA from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 17.900 NA in 2000 and a record low of 12.000 NA in 2016. Italy IT: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s Italy – Table IT.World Bank.WDI: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

BackgroundWhile current recommendations on exercise type and volume have strong experimental bases, there is no clear evidence from large-sized studies indicating whether increasing training intensity provides additional benefits to subjects with type 2 diabetes. ObjectiveTo compare the effects of moderate-to-high intensity (HI) versus low-to-moderate intensity (LI) training of equal energy cost, i.e. exercise volume, on modifiable cardiovascular risk factors. DesignPre-specified sub-analysis of the Italian Diabetes and Exercise Study (IDES), a randomized multicenter prospective trial comparing a supervised exercise intervention with standard care for 12 months (2005–2006). SettingTwenty-two outpatient diabetes clinics across Italy. PatientsSedentary patients with type 2 diabetes assigned to twice-a-week supervised progressive aerobic and resistance training plus exercise counseling (n = 303). InterventionsSubjects were randomized by center to LI (n = 142, 136 completed) or HI (n = 161, 152 completed) progressive aerobic and resistance training, i.e. at 55% or 70% of predicted maximal oxygen consumption and at 60% or 80% of predicted 1-Repetition Maximum, respectively, of equal volume. Main Outcome Measure(s)Hemoglobin (Hb) A1c and other cardiovascular risk factors; 10-year coronary heart disease (CHD) risk scores. ResultsVolume of physical activity, both supervised and non-supervised, was similar in LI and HI participants. Compared with LI training, HI training produced only clinically marginal, though statistically significant, improvements in HbA1c (mean difference −0.17% [95% confidence interval −0.44,0.10], P = 0.03), triglycerides (−0.12 mmol/l [−0.34,0.10], P = 0.02) and total cholesterol (−0.24 mmol/l [−0.46, −0.01], P = 0.04), but not in other risk factors and CHD risk scores. However, intensity was not an independent predictor of reduction of any of these parameters. Adverse event rate was similar in HI and LI subjects. ConclusionsData from the large IDES cohort indicate that, in low-fitness individuals such as sedentary subjects with type 2 diabetes, increasing exercise intensity is not harmful, but does not provide additional benefits on cardiovascular risk factors. Trial Registrationwww.ISRCTN.org ISRCTN-04252749.

The hospitalization rate for untreated diabetes in Italy appeared to be significantly higher in the Autonomous Province of Bolzano, compared to the rest of the country. In fact, according to data from 2018, Italy registered an hospitalization for untreated diabetes of *****, whereas rate recorded in the Autonomous Province of Bolzano was as high as *****. By contrast, the rate in the region of Aosta Valley was as low as ****.

Background: The steady increase in type 2 diabetes prevalence and the availability of new antidiabetic drugs (AD) have risen the use of these drugs with a change in the patterns of specific drug utilization. The complexity of this treatment is due to successive treatment initiation, switching and addition in order to maintain glycaemic control. The aim of this study was to describe the utilization patterns of ADs at initiation, treatment addition, and switching profiles and to measure factors influencing persistence to therapy.Methods: Retrospective observational study. Data were retrieved from the Campania Regional Database for Medication Consumption. Population consisted of patients receiving at least one prescription of ADs between January 1 and December 31, 2016. We calculated time to treatment switching or add-on as median number of days and interquartile range (IQR). Persistence rates were estimated using the Kaplan–Meier method. We used Cox regression models to estimate the likelihood of non-persistence over 1 year of follow-up. Hazard ratios and 95% confidence intervals were calculated.Results: Of 14,679 patients, 86.9% started with monotherapy and 13.1% with combination therapy. Most common initial treatment was metformin in both monotherapy and combination therapy. First-line prescription of sulfonylurea was observed in 6.9% of patients aged 60–79 years and in 10.8% of patients aged ≥80 years. Patients starting with metformin showed fewer treatment modifications (10.4%) compared to patients initiating with sulfonylureas (35.2%). Newer ADs were utilized during treatment progression. Patients who initiated with sulfonylurea were approximately 70% more likely to discontinue treatment compared to those initiated on metformin. Oldest age group (≥80 years) was more likely to be non-persistent, and likelihood of non-persistence was highest in polymedicated patients. Patients changing therapy were more likely to be persistent.Conclusions: Our results show that treatment of T2D in Italy is consistent with clinical guidelines. Even if newer ADs were utilized during disease progression, they seem not to be preferred in patients with a higher comorbidity score, although these patients could benefit from this kind of treatment. Our study highlights patients’ characteristics that might help identify those who would benefit from counselling from their health-care practitioner on better AD usage.